Business Description
Repare Therapeutics Inc
NAICS : 541714
SIC : 3741
Description
Repare Therapeutics Inc is a precision oncology company engaged in the discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 62.84 | |||||
| Equity-to-Asset | 0.75 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.22 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 4.25 | |||||
| Beneish M-Score | 120.75 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -53.3 | |||||
| 3-Year EPS without NRI Growth Rate | -46.2 | |||||
| 3-Year FCF Growth Rate | -40.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.21 | |||||
| 9-Day RSI | 48.88 | |||||
| 14-Day RSI | 53.58 | |||||
| 6-1 Month Momentum % | 51.34 | |||||
| 12-1 Month Momentum % | -48.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.31 | |||||
| Quick Ratio | 6.31 | |||||
| Cash Ratio | 5.99 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -38.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -23.98 | |||||
| Net Margin % | -21.31 | |||||
| ROE % | -9.9 | |||||
| ROA % | -7.47 | |||||
| ROIC % | -72.73 | |||||
| ROC (Joel Greenblatt) % | -244.57 | |||||
| ROCE % | -9.48 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 5.85 | |||||
| PB Ratio | 2.2 | |||||
| Price-to-Tangible-Book | 2.2 | |||||
| Price-to-Free-Cash-Flow | 501.88 | |||||
| Price-to-Operating-Cash-Flow | 178.44 | |||||
| EV-to-EBIT | -10.71 | |||||
| EV-to-EBITDA | -11.46 | |||||
| EV-to-Revenue | 2.57 | |||||
| EV-to-Forward-Revenue | 206.48 | |||||
| EV-to-FCF | 45.95 | |||||
| Price-to-Net-Current-Asset-Value | 2.35 | |||||
| Price-to-Net-Cash | 2.53 | |||||
| Earnings Yield (Greenblatt) % | -9.34 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RPTX
Peter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 120.509 | ||
| EPS (TTM) ($) | -0.73 | ||
| Beta | 0 | ||
| Volatility % | 75.3 | ||
| 14-Day RSI | 53.58 | ||
| 14-Day ATR ($) | 1.228348 | ||
| 20-Day SMA ($) | 15.971 | ||
| 12-1 Month Momentum % | -48.11 | ||
| 52-Week Range ($) | 8.065 - 27.4 | ||
| Shares Outstanding (Mil) | 41.96 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Repare Therapeutics Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Repare Therapeutics Inc Analysis
Share your researchHeadlines
See More
No news.